ABM was acquired by Cadence Health Capital last month. A new leadership team at the neurology-forward sleep company plans to streamline operations and expand the clinical reach of validated technologies for sleep apnea, insomnia, and neurodegenerative disease.
Read More
How evolving diagnoses and unclear terminology can undermine patient trust—and what clinicians can do about it.
Read More
I tested two AI “selfie screeners” for sleep apnea. Here is a look at their current clinical applications, and why a “false positive” might be a glimpse into your health’s future.
Read More
New survey data highlights what sleep lab supervisors value most in EEG equipment setups, alongside common troubleshooting challenges.
Read More
As mechanism-based orexin agonists get close to market, sleep physicians may feel compelled to reduce ambiguity between narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia diagnoses.
Read More